title: Comparative clinical features of stage A1 and stage A2 prostate cancers. Is the concept of stage A changing from the current status?
abstract: We surveyed the comparative clinical features of patients with stage A1 and stage A2 prostate cancer. Preoperatively, prostate specific antigen (PSA) level was elevated in 50.0% of stage A2 patients as compared to 18.2% of stage A1 patients. Compared to low positivity of prostatic acid phosphatase in 12.5% of stage A2 and in 0% of stage A1, PSA was more sensitive to the presence of incidental carcinoma. During the observation period (mean 35.7 months) no stage A patient died of cancer. No evidence of the disease showed significantly higher rate, and death without cancer was significantly lower in stage A1.
authors.affiliation: Department of Urology, Kanazawa University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kunimi
authors.forename: T
authors.initials: T
authors.lastname: Amano
authors.forename: S W
authors.initials: SW
authors.lastname: Lee
authors.forename: H
authors.initials: H
authors.lastname: Fuse
authors.forename: T
authors.initials: T
authors.lastname: Uchibayashi
authors.forename: K
authors.initials: K
authors.lastname: Miyazaki
authors.forename: M
authors.initials: M
authors.lastname: Ohkawa
mesh_terms: D000135:Acid Phosphatase / Q000097:blood*; D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology* / Q000628:therapy; D000368:Aged; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies
chemical_list: D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen